ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

Prior treatment

• Subjects currently treated by immunomodulators, biologics, JAK inhibitors, S1PR modulator and investigational drugs and within the last three months. A history of immunomodulator or biologic or JAK inhibitor or S1PR modulator and investigational drugs use in the past is not an exclusion criteria.

Other

• Any subject who meets one of the following criteria will not qualify for entry in the study:
• Subjects recruited during hospitalization, or via the urgency department for active UC, or during an unscheduled visit for emergency reasons.
• UC patients with a total colectomy, with or without IPAA
• Patients with indetermined colitis (IBDU)
• Women that are pregnant

• Male or female ≥ 18 years
• Confirmed diagnosis of UC
• Patients with PRO-2 ≤ 1, with ≤ 1 for stool frequency and 0 for rectal bleeding in the last 3 days before the visit.
• Recruitment during a routine follow-up visit.
• Subjects to whom 5-ASA treatment has been prescribed for at least 6 months (any type of oral and/or rectal 5 ASA, any dosage) and with the dose of 5-ASA stable for at least 2 weeks (including suppositories) prior to inclusion.
• Prescription of 5-ASA is within the locally approved Summary of Product Characteristics (SmPCs)
• Subjects free of concomitant UC medication (corticosteroids, immunomodulators, biologics, JAK inhibitors, S1PR modulator or investigational drugs) for at least 3 months
• Subject or the subject's legally acceptable representative have the capacity to understand and (voluntary) sign an informed consent form
• Be able to adhere to the study visit schedule and other protocol requirements